Amgen (NASDAQ: AMGN) provided an update last week on a late-stage trial evaluating its PDE4 inhibitor Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis in patients aged 6 to 17 years. The one-year data revealed that 56.3% of participants achieved clear or almost clear skin, while 71.4% demonstrated improvement in disease severity and skin involvement.
Among those who switched from placebo to Otezla at week 16, 52.5% attained clear or almost clear skin, with 75.4% showing improvements in disease severity and skin involvement. The safety profile of Otezla in this pediatric population was consistent with findings previously reported in adults.- Flcube.com
